SEC Form 4
Pelthos Therapeutics Inc. (PTHS) insider trading
In the 12 months to Oct 26, 2026, 5 PTHS insiders reported open-market sales of $486.3K across 13 filings; one director bought $1.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $486.3K
- 13 filings · 5 insiders
- Open-market purchases
- $1.0M
- 1 filing · Todd C. Davis, Director
- Pre-arranged sales (10b5-1)
- 11 of 13
- $165.7K of $486.3K sold (34%)
Who traded PTHS, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
PTHS daily close from Oct 27, 2025 to Oct 26, 2026, between $16.29 and $37.42, last $16.29. 13 sale and 1 purchase filings by 6 insiders, marked at their filing dates. Todd C. Davis, Director: bought $1.0M across 1 filing, first filed Jun 15, 2026, last Jun 15, 2026. Ezra M. Friedberg, Director: sold $325.8K across 5 filings, first filed Nov 26, 2025, last Oct 6, 2026. Peter Greenleaf, Director: sold $54.4K across 3 filings, first filed Apr 6, 2026, last Oct 6, 2026. Matthew Pauls, Director: sold $53.5K across 3 filings, first filed Apr 6, 2026, last Oct 6, 2026. Knuettel Francis II, CFO, Treas & Secty: sold $40.3K across 1 filing, first filed May 26, 2026, last May 26, 2026. Richard Malamut, Director: sold $12.3K across 1 filing, first filed Apr 6, 2026, last Apr 6, 2026.
Largest mark · tap a row for others
Todd C. Davis · Director
Purchase $999,983
35,948 shares at $27.82 avg
Filed Jun 15, 2026 · traded Jun 11
Close on filing date $26.50
Todd C. Davis · Director
Director
$1.0M boughtEzra M. Friedberg · Director
Director
$325.8K soldPeter Greenleaf · Director
Director
$54.4K soldMatthew Pauls · Director
Director
$53.5K soldKnuettel Francis II · CFO, Treas & Secty
CFO, Treas & Secty
$40.3K soldRichard Malamut · Director
Director
$12.3K soldOpen-market trades
14 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Todd C. Davis | Director | — | $1.0M | 1 | — | |
| Ezra M. Friedberg | Director | $325.8K | — | 5 | 14% of sales | |
| Peter Greenleaf | Director | $54.4K | — | 3 | 100% of sales | |
| Matthew Pauls | Director | $53.5K | — | 3 | 100% of sales | |
| Knuettel Francis II | CFO, Treas & Secty | $40.3K | — | 1 | — | |
| Richard Malamut | Director | $12.3K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Matthew Pauls Director | SalePre-arranged (10b5-1) | 786 | $21.00 | $16.5K | 13,578 | |
traded | Ezra M. Friedberg Director | SalePre-arranged (10b5-1) | 558 | $20.72 | $11.6K | 80,484 | |
traded | Peter Greenleaf Director | SalePre-arranged (10b5-1) | 797 | $21.17 | $16.9K | 23,087 | |
traded | Peter Greenleaf Director | SalePre-arranged (10b5-1) | 797 | $26.13 | $20.8K | 23,884 | |
traded | Matthew Pauls Director | SalePre-arranged (10b5-1) | 786 | $26.16 | $20.6K | 14,458 | |
traded | Ezra M. Friedberg Director | SalePre-arranged (10b5-1) | 558 | $26.09 | $14.6K | 81,066 | |
traded | Ezra M. Friedberg Director | SalePre-arranged (10b5-1) | 283 | $27.29 | $7.7K | 81,600 | |
traded | Todd C. Davis Director | Purchase | 35,948 | $27.82 | $1.0M | 75,331 | |
traded | Knuettel Francis II CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40.3K | 11,316 | |
traded | Peter Greenleaf Director | SalePre-arranged (10b5-1) | 797 | $20.92 | $16.7K | 24,681 | |
traded | Matthew Pauls Director | SalePre-arranged (10b5-1) | 786 | $20.92 | $16.4K | 15,521 | |
traded | Ezra M. Friedberg Director | SalePre-arranged (10b5-1) | 558 | $20.92 | $11.7K | 82,292 | |
traded | Richard Malamut Director | SalePre-arranged (10b5-1) | 590 | $20.92 | $12.3K | 27,422 | |
traded | Ezra M. Friedberg Director | Sale | 10,000 | $28.03 | $280.3K | 32,001 |
GET /stocks/filings/vX/form-4?tickers=PTHS&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PTHS"
],
"issuer_cik": "0001919246",
"owner_cik": "0001679440",
"accession_number": "0001919246-26-000130",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-02",
"issuer_name": "Pelthos Therapeutics Inc.",
"issuer_trading_symbol": "PTHS",
"owner_name": "Friedberg Ezra M",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 558,
"transaction_price_per_share": 20.7169,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 80484,
"transaction_value": 11560.0302,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."
}
]
},
{
"tickers": [
"PTHS"
],
"issuer_cik": "0001919246",
"owner_cik": "0001363683",
"accession_number": "0001919246-26-000131",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-02",
"issuer_name": "Pelthos Therapeutics Inc.",
"issuer_trading_symbol": "PTHS",
"owner_name": "Greenleaf Peter",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 797,
"transaction_price_per_share": 21.17,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 23087,
"transaction_value": 16872.49,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 21 records
- Option exercises2 records
- Tax withholding1 record
- Grants and awards16 records
- Gifts1 record
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Pelthos Therapeutics Inc.'s CEO sold stock?
No. Scott M. Plesha (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is PTHS’s insider data?
These are PTHS Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PTHS insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PTHS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.